Easton Pharmaceuticals Signs LOI to Acquire a Cosmetic Anti-Aging & Beauty Care Line of Products Including a Product to Compl...
2013年9月27日 - 10:00PM
ビジネスワイヤ（英語）
Easton Pharmaceuticals, Inc. (OTC: EAPH) a specialty
pharmaceutical company that designs, develops, and markets a
premium array of topically-delivered therapeutic healthcare
products, today announces it has signed a letter of intent to
acquire a line of Anti-Ageing and beauty care products.
The company has 60 days to perform its due diligence and review
the line of products as well as any intellectual property including
any patents or patent pendings that may come with the acquisition.
The list of products includes an Anti-Ageing HEMP based Anti-Ageing
Moisturizer, a product fortified with HEMP oil which is derived
from a different form of Cannabis plant known to have high amounts
of proteins and amino acids to compliment the companies medical
Marijuana initiatives. As well as encompassing HEMP oil, the HEMP
based Anti-Ageing moisturizer uses pure botanical natural
ingredients derived from plants, including organic herbs. Other
products include a specialized anti-ageing serum fortified with
high amounts of Vitamin C, a skin discoloration / age spot
treatment gel and an anti-cellulite varicose veins treatment
system.
The Product line and the company the products are being acquired
from will stay confidential until closing of a final definitive
agreement, which the company believes has a high probability of
closing. Both companies have 60 days in which to come to terms and
close on the final agreement. Whether the transaction closes or
not, it is anticipated that Easton will be providing assistance to
these products by lending the use of its own technology to help
improve the products efficacy and delivery through the skin. Should
the deal close, this acquisition will bring Easton into the $426
Billion a year Cosmetics Industry which will coincide and
complement its therapeutic line of products including its main
product, “VIORRA”, a product to help treat FSAD (Female Sexual
Arousal Disorder) utilizing ingredients which the FDA classifies as
safe (GRAS).
In other developments, the Company has received its shipment of
its main ingredient HA for final trial batch samples of Viorra and
its other products, but is still waiting on additional ingredients
which are expected shortly. Once complete, the trial samples will
be shipped to Mexico and other parts of Latin America where the
company anticipates completing and obtaining governmental
regulatory approval which would allow the products to be sold in
those vast markets. Although its new revised website has
experienced delays for various reasons including final design
labeling, all of these products as well as its current line of
therapeutic products and recently acquired FSAD Drug will be listed
and detailed very shortly.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company
that designs, develops, and markets a premium array of
topically-delivered drugs, therapeutic healthcare products and
beauty anti-aging cosmetic products. Its therapeutic healthcare
products are focused on conditions that impact a large and
expanding number of consumers including health and lifestyle issues
related to female and male sexual dysfunction, treatment of certain
pain, wound healing, scar and stretch marks, cellulite and varicose
veins. The world market for these conditions is in excess of $10
billion while the world market for anti-ageing / beauty cosmetics
is estimated at over $426 Billion.
The company's updated gel formulation is an innovative and
thought to be unique transdermal delivery system. Easton
Pharmaceuticals’ flagship product, VIORRA, is an over-the-counter
aid for the treatment to restore and improve vaginal moisture and
elasticity which has a very positive effect on women’s sexual
desire and arousal, FSAD (Female Sexual Arousal Disorder) the world
market for these female conditions are in excess of $2 billion.
VIORRA is a topical, daily-use product classified by the FDA as
containing Generally Recognized as Safe ingredients.
For More Information Visithttp://www.eastonpharma.com
http://www.ashleybiomedical.com
Safe Harbor
This news release may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
(The "Act"). In particular, when used in the preceding of
discussion, the words "pleased," "plan," "confident that,"
"believe," "expect," or "intent to" and similar conditional
expressions are intended to identify forward-looking statements
within the meaning of the Act and are subject to the safe harbor
created by the Act. Such statements are subject to certain risks
and uncertainties and actual results could differ materially from
those expressed in any of the forward-looking statements. Such
risks and uncertainties include, but are not limited to, market
conditions, general acceptance of the company's products and
technologies, competitive factors, the ability to successfully
complete additional or adequate financing and other risks and
uncertainties as stated in the company's financial reports and
filings.
Contact:
Carla Pepe, Marketing DirectorEaston Pharmaceuticals
Inc.Tel: +1(416) 619-0291Tel: +1(347)
284-0192Media and Investor Relations:
info@lamindustries.com &
info@ashleybiomedical.com
Easton Pharmaceuticals Inc.Carla Pepe, Marketing
DirectorTel: +1(416) 619-0291Tel: +1(347)
284-0192orMedia and Investor
Relations:info@lamindustries.cominfo@ashleybiomedical.com
Easton Pharmaceuticals (CE) (USOTC:EAPH)
過去 株価チャート
から 12 2024 まで 1 2025
Easton Pharmaceuticals (CE) (USOTC:EAPH)
過去 株価チャート
から 1 2024 まで 1 2025
